These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 11764248)

  • 1. Decision-theoretic designs for pre-phase II screening trials in oncology.
    Stallard N; Thall PF
    Biometrics; 2001 Dec; 57(4):1089-95. PubMed ID: 11764248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size determination for phase II clinical trials based on Bayesian decision theory.
    Stallard N
    Biometrics; 1998 Mar; 54(1):279-94. PubMed ID: 9544522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decision theoretic designs for phase II clinical trials with multiple outcomes.
    Stallard N; Thall PF; Whitehead J
    Biometrics; 1999 Sep; 55(3):971-7. PubMed ID: 11315037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials.
    Thall PF; Sung HG
    Stat Med; 1998 Jul; 17(14):1563-80. PubMed ID: 9699230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian decision approach for sample size determination in phase II trials.
    Leung DH; Wang YG
    Biometrics; 2001 Mar; 57(1):309-12. PubMed ID: 11252615
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Phases 0, 1 and 2 oncology clinical trials: current questions].
    Penel N; Fournier C; Stéphanie C
    Bull Cancer; 2010 Jan; 97(1):55-63. PubMed ID: 20080458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decision-theoretic designs for small trials and pilot studies: A review.
    Hee SW; Hamborg T; Day S; Madan J; Miller F; Posch M; Zohar S; Stallard N
    Stat Methods Med Res; 2016 Jun; 25(3):1022-38. PubMed ID: 26048902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Performance of Fixed-Horizon, Look-Ahead Procedures Compared to Backward Induction in Bayesian Adaptive-Randomization Decision-Theoretic Clinical Trial Design.
    Lipsky AM; Lewis RJ
    Int J Biostat; 2019 Feb; 15(1):. PubMed ID: 30726189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation.
    Thall PF; Estey EH
    Stat Med; 1993 Jul; 12(13):1197-211. PubMed ID: 8210822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New designs for the selection of treatments to be tested in randomized clinical trials.
    Simon R; Thall PF; Ellenberg SS
    Stat Med; 1994 Mar 15-Apr 15; 13(5-7):417-29. PubMed ID: 8023026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Designing a series of decision-theoretic phase II trials in a small population.
    Hee SW; Stallard N
    Stat Med; 2012 Dec; 31(30):4337-51. PubMed ID: 22927289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sample sizes for phase II clinical trials derived from Bayesian decision theory.
    Brunier HC; Whitehead J
    Stat Med; 1994 Dec 15-30; 13(23-24):2493-502. PubMed ID: 7701149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bayesian decision sequential analysis with survival endpoint in phase II clinical trials.
    Zhao L; Woodworth G
    Stat Med; 2009 Apr; 28(9):1339-52. PubMed ID: 19226557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian decision-theoretic group sequential clinical trial design based on a quadratic loss function: a frequentist evaluation.
    Lewis RJ; Lipsky AM; Berry DA
    Clin Trials; 2007; 4(1):5-14. PubMed ID: 17327241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implementing a decision-theoretic design in clinical trials: why and how?
    Palmer CR; Shahumyan H
    Stat Med; 2007 Nov; 26(27):4939-57. PubMed ID: 17582801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening designs for drug development.
    Rossell D; Müller P; Rosner GL
    Biostatistics; 2007 Jul; 8(3):595-608. PubMed ID: 17030589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new statistical decision rule for single-arm phase II oncology trials.
    Chen Y; Chen Z; Mori M
    Stat Methods Med Res; 2016 Feb; 25(1):118-32. PubMed ID: 22461073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decision-theoretic designs for phase II clinical trials allowing for competing studies.
    Stallard N
    Biometrics; 2003 Jun; 59(2):402-9. PubMed ID: 12926725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Bayesian decision-theoretic sequential response-adaptive randomization design.
    Jiang F; Jack Lee J; Müller P
    Stat Med; 2013 May; 32(12):1975-94. PubMed ID: 23315678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Admissible two-stage designs for phase II cancer clinical trials.
    Jung SH; Lee T; Kim K; George SL
    Stat Med; 2004 Feb; 23(4):561-9. PubMed ID: 14755389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.